DYN Q3 2020 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$14M

Net Income

-$14M

EPS (Diluted)

$-0.31

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$381M

Total Liabilities

$15M

Stockholders' Equity

$367M

Cash & Equivalents

$380M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$14M	-$4M	-272.6%
Net Income	-$14M	-$6M	-137.1%